Mayo Clinic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mayo Clinic sits in the top decile of US sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count).
Mayo Clinic: 2,844 sponsored US clinical trials, 544 recruiting.
Mayo Clinic sponsors 2,844 registered US clinical trials on ClinicalTrials.gov, 544 of them currently recruiting, and 1,816 completed. 252 of these trials are in Phase 3-4 (later-stage) and 821 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 36 trials.
Top-decile sponsor footprint
Mayo Clinic ranks in the top decile of sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,844 total, page 8 of 57
Social Determinants of Health in Hepatobiliary Cancer Patients
NCT06053333
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
NCT05898646
Efficacy of Nerve Blocks for Episodic Migraine
NCT05734625
A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle
NCT05856136
A Clinical Registry of Spontaneous Intracranial Hypotension
NCT05922514
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
NCT05789394
Adult Spinal Deformity Surgery Real-World Functional Activity
NCT05611775
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NCT05876923
A Study of Latin Dance for Post- Lung Transplant
NCT05924113
A Study to Analyze the Role of Sympathetic Nervous System in Spontaneous Coronary Artery Dissection
NCT05699200
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
NCT05030298
Assessing the Effect of Computer-based Auditory Training on Adult Cochlear Implant Speech and Quality-of-life Outcomes
NCT06607146
Understanding of Genetics by Men at Risk for Prostate Cancer
NCT04550845
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
NCT05753306
Noninvasive Ultrasound Assessment of Detrusor Dysfunction
NCT05652023
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
NCT05357690
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
NCT05538247
Prospective Carotid Artery Stenosis Trial
NCT05724836
Study of Transcranial Direct Current Stimulation to Treat Epilepsy
NCT05673915
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
NCT05746325
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
NCT05549661
Real-Time Cholangioscopy Artificial Intelligence Evaluation of Biliary Strictures
NCT05779436
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
NCT05755269
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT05557877
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
NCT05517928
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
NCT05541016
3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
NCT05704283
Evaluation of Gender-Affirming Treatments on Pulmonary Function in Transgender and Gender Diverse Patients
NCT05587751
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
NCT05456243
Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
NCT05426200
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
NCT05465954
Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)
NCT05629377
Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors
NCT05584449
Automating Delirium Severity in the ICU
NCT06172491
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05388006
Study of Disrupted Sleep in Somali Americans
NCT05411029
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
NCT05518903
Novel Treatment for Rotator Cuff Tears
NCT05590494
Adverse Outcomes and Mortality in Liver Transplant
NCT05477277
Prospective Assessment of HPV Associated Anogenital Pathology in Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma, PAP-OP Study
NCT06115772
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
NCT04892277
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer
NCT05507879
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
NCT05547698
Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology
NCT05206955
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT05465941
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
NCT05525845
Clinical Impact of Cardiac Photon Counting CT
NCT05240807
Intracardiac Flow Assessment in Cardiac Amyloidosis
NCT05379101
Bladder Bank (a Prospective Banking Study)
NCT06109857
Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients
NCT05612100
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 435 |
| Phase 2 | 386 |
| Phase 3 | 86 |
| Phase 4 | 166 |
Therapeutic Areas
What is open in the Mayo Clinic pipeline
544 recruiting of 2,844 indexed (19% open); 1,816 completed (64%).
Phase mix: 252 late (III/IV) vs 821 early (I/II) (early-phase heavy).
Top condition: Healthy (36 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.